As of 13:39 on January 17, 2025, the Hong Kong stock pharmaceutical ETF (159718) rose 1.62%, the latest price was 0.56 yuan, and the intraday turnover has reached 13.2137 million yuan, with a turnover rate of 6.23%. The tracking index CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) rose strongly by 2.31%, the constituent stocks MicroPort Robot-B (02252) rose by 7.31%, Chi-Med (00013) rose by 6.51%, Innovent Biologics (01801) rose by 6.33%, and stocks such as 3SBio (01530) and InnoCare (09969) followed suit.

Medical Innovation ETF (516820) rose 0.31%, the latest price was 0.32 yuan, and the intraday turnover has reached 20.8933 million yuan. The tracking index CSI Pharmaceutical and Medical Device Innovation Index (931484) rose 0.42%, the constituent stocks Yirui Technology (688301) rose 8.13%, Allist (688578) rose 7.69%, Tebao Biotech (688278) rose 6.37%, Aibo Medical (688050) rose 2.72%, and China Resources Sanjiu (000999) rose 2.27%.

In the long run, as of January 16, 2025, Hong Kong stock pharmaceutical ETFs have risen by 7.78% in the past six months, ranking 1/4 of comparable funds. Medical Innovation ETF has risen 0.95% in the past 1 week, ranking 1/2 of comparable funds.

In terms of scale, the scale of medical innovation ETF has increased by 23.4064 million yuan in the past 1 week, achieving significant growth, and the new scale ranks 1/2 of comparable funds.

In terms of shares, the share of medical innovation ETF has increased by 14 million since the beginning of this month, achieving significant growth, and the new share ranks 1/2 of comparable funds.

In terms of fund inflow, the latest net inflow of medical innovation ETF was 6.7489 million yuan. In the long run, there have been 13 net inflows of funds in the past 22 trading days, with a total of 26.5464 million yuan and an average daily net inflow of 1.2067 million yuan. The data shows that leveraged funds continue to be deployed. The latest financing purchase amount of medical innovation ETF reached 4.8066 million yuan, and the latest financing balance reached 82.1838 million yuan.

From the perspective of valuation, the latest price-to-earnings ratio (PE-TTM) of the CSI Hong Kong Stock Connect Medical and Health Composite Index tracked by the Hong Kong Pharmaceutical ETF is only 28.18 times, which is at the quantile of 13.83% in the past five years, that is, the valuation is lower than the time of more than 86.17% in the past five years, which is at a historical low.

It is worth noting that the valuation of the CSI Pharmaceutical and Medical Device Innovation Index tracked by the medical innovation ETF is at a historical low, with the latest price-to-book ratio of 4.39 times, which is lower than the index of more than 86.88% in the past five years, and the valuation is cost-effective.

On January 16, the Office of the National Medical Security Administration issued a notice on promoting the reform of instant settlement of the basic medical insurance fund, clarifying the reform goals, supported by the national unified medical insurance information platform, while doing a good job in the prepayment of the medical insurance fund, fully considering the needs and capabilities of designated medical institutions, in 2025, about 80% of the country's overall areas will basically achieve instant settlement, and in 2026, all the country's overall areas will achieve instant settlement. The National Health Insurance Administration requires all localities to adhere to the combination of optimizing traditional settlement and innovative settlement methods, fully compressing the process and time, and reducing the original 30 working days from the next day of the declaration deadline of designated medical institutions to the allocation of medical insurance funds to 20 working days. Adhere to the combination of fund prepayment and instant settlement, which not only increases the total cash of medical institutions through fund prepayment, but also accelerates the cash flow of medical institutions through instant settlement. Adhere to the combination of pilot and comprehensive promotion, guide local governments to proceed from reality, reasonably determine the settlement model, and gradually promote the completion of relevant work according to the time node.

On January 17, 2025, the medical insurance department of the National Health Insurance Administration held a press conference on the theme of "Protecting People's Health and Empowering Economic Development". At the meeting, it was introduced that in 2024, China's medical insurance fund will be balanced and slightly surplused, and the medical insurance fund will be safe and sustainable.

The CSI Hong Kong Stock Connect Medical and Health Composite Index selects 50 securities of listed companies in the medical and health industry with good liquidity and large market capitalization from the Hong Kong Stock Connect as index samples to reflect the overall performance of the securities of medical and health listed companies within the scope of Hong Kong Stock Connect.

According to the data, as of December 31, 2024, the top 10 weighted stocks of the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) were WuXi Biologics (02269), BeiGene (06160), Innovent Biologics (01801), Akeso Biologics (09926), CSPC Pharmaceutical Group (01093), Sino Biopharma (01177), JD Health (06618), Sinopharm Group (01099), Zai Lab (09688), and WuXi AppTec(02359), the top ten weighted stocks accounted for 57.44%.

Hong Kong Pharmaceutical ETF (159718), OTC Connect (Ping An CSI Hong Kong Pharmaceutical ETF Connect A: 019598; Ping An CSI Hong Kong Pharmaceutical ETF Connect C: 019599).

The

CSI Pharmaceutical and Medical Device Innovation Index selects 30 listed companies with good profitability and certain growth and R&D innovation capabilities from the listed companies in the medical and health industry as index samples to reflect the overall performance of the securities of listed pharmaceutical and medical device companies with both profitability and growth.

According to the data, as of December 31, 2024, the top 10 weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index (931484) are Mindray Medical (300760), WuXi AppTec (603259), Hengrui Pharmaceutical (600276), Aier Ophthalmology (300015), United Imaging Medical (688271), Kelun Pharmaceutical (002422), Changchun High-tech (000661), Zhifei Biotechnology (300122), and Huadong Medicine ( 000963) and new industries (300832), the top ten weighted stocks accounted for 66.25% of the total.